[In Focus] Establishing a sustainable academic point-of-care network for CAR T-cell therapy

Chimeric antigen receptor (CAR) T-cell therapy has revolutionised the treatment of B-cell malignancies, offering durable responses for patients with relapsed or refractory disease. However, access globally remains limited due to high costs, centralised production models, and logistical challenges. Despite approvals from the US Food and Drug Administration, European Medicines Agency, and other regulatory bodies, less than 5% of eligible patients worldwide receive CAR T-cell therapy. Socioeconomic and geographical barriers, as well as delays related to complex manufacturing, further challenge timely access.